CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online ...

A blood test now in the works could be a better predictor of prostate cancer than current PSA tests. It's called the IsoPSA. It's being developed by the Cleveland Clinic, the Cleveland VA Medical ...

IsoPSA Test Evaluates Prostate Cancer-Specific Structural Variants of the PSA Protein to Aid in the Diagnosis of High-Grade Prostate Cancer CLEVELAND, December 01, 2025--(BUSINESS WIRE)--Cleveland ...

SAN FRANCISCO -- An assay that identifies abnormal PSA proteins showed promise as an aid to avoid unnecessary prostate biopsies triggered by worrisome PSA test results, according to data reported here ...

A new blood-based diagnostic test (IsoPSA) for prostate cancer that evaluates structural changes in prostate-specific antigen could reduce unnecessary biopsies and identify the right patients that ...

A new blood test called IsoPSA has been developed by researchers, that helps in detecting prostate cancer and reduces the rate of biopsies by almost 50 percent. IsoPSA, a new blood test detects ...

A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA ...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today two ...

A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic ...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company focused on the development of next-generation diagnostic tests for early detection of cancers, announced ...

Cofounding CEO Arnon Chait to remain with company as Chief Innovation Officer Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, has named Michael Iskra as its new ...

Using the prostate-specific antigen test to screen for prostate cancer is controversial: First, doctors used to perform it on nearly every man over 50. Then in 2012, the U.S. Preventive Task Force ...